Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Microbial Ecosystem Therapeutics 2 (MET-2) & Clostridioides difficile infection (CDI) (recurrent)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

NCT02865616
MET-2 seems to be a safe, effective, and well-tolerated option for patients experiencing recurrent C difficile infections (1)

(1) Kao et al. 2021 Lancet Gastroenterol Hepatol 6(4): 282-291

The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial
Kao et al. 2021 Lancet Gastroenterol Hepatol 6(4): 282-291
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech et al. 2024 Clinical Microbiology and Infection 30: 462-468
Review

7/1/2026